Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zebulun Purdin"'
Autor:
Nathan Denlinger, Ying Huang, Zachary Braunstein, Audrey Sigmund, Amneet Bajwa, Nilesh Kapoor, Akwasi Agyeman, Scott Fisher, Zebulun Purdin, Alison Neal, Filiz Yucebay, Julianna Roddy, Jonathan Brammer, Basem William, Ayman Saad, Sam Penza, Timothy Voorhees, Adam Kittai, Marcos de Lima, Sumithira Vasu, Samantha Jaglowski
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S381-S382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ec619b23be4dedf1c5acf4e0ad2ba41
https://doi.org/10.1016/s2152-2650(22)01544-0
https://doi.org/10.1016/s2152-2650(22)01544-0
Autor:
Nathan Denlinger, Ying Huang, Zachary Braunstein, Audrey Sigmund, Amneet Bajwa, Nilesh Kapoor, Akwasi Agyeman, Scott Fisher, Zebulun Purdin, Alison Neal, Filiz Yucebay, Julianna Roddy, Jonathan Brammer, Basem William, Ayman Saad, Sam Penza, Timothy Voorhees, Adam Kittai, Marcos de Lima, Sumithira Vasu, Samantha Jaglowski
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S170
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4aa481708e77627e86b7e984ede2f78
https://doi.org/10.1016/s2152-2650(22)01049-7
https://doi.org/10.1016/s2152-2650(22)01049-7
Autor:
Akwasi Agyeman, Sumithira Vasu, Basem M. William, Ayman Saad, Jonathan E. Brammer, Julianna Roddy, Filiz Yucebay, Zebulun Purdin, Ying Huang, Sam Penza, Samantha Jaglowski, Zachary Braunstein, Alison Neal, Nathan Denlinger
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S266
Background Axicabtagene ciloleucel (A) and Tisagenlecleucel (T) are FDA approved CAR T cell products that have changed treatment (tx) for patients (pts) w/ relapsed/refractory lymphoma. The high tx cost has implications in selection of pts for CAR T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db97017a277f91a928d409291d49f9db
https://doi.org/10.1016/j.bbmt.2019.12.432
https://doi.org/10.1016/j.bbmt.2019.12.432
Autor:
Nicole Grieselhuber, Basem M. William, Ashley E. Rosko, Sarah A Wall, Andrew Schaefer, Meixiao Long, Alice S. Mims, Samantha Jaglowski, Don M. Benson, Tara Hoelscher, Zebulun Purdin, Misty Lamprecht, Bradley W. Blaser, Yvonne A. Efebera, Sumithira Vasu, Sam Penza, Karilyn Larkin, Hannah Choe, Joseph E. Maakaron, Jacquela Robinson, Caner Saygin, Jonathan E. Brammer
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S171
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor treatment outcomes when treated with traditional chemoimmunotherapy. Superior outcomes have been observed with the 2 CAR-T cell products approved by the US FDA; tisagen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03078bf84dcb55026c1c58522e177658
https://doi.org/10.1016/j.bbmt.2018.12.311
https://doi.org/10.1016/j.bbmt.2018.12.311